|
|
|
MK-1167
Mechanism of Action: MK-1167 is an alpha-7 nicotinic acetylcholine receptor positive allosteric modulator.
MK-1167 is being developed under a collaboration with Neuphoria.
|
Neuroscience |
|
Small molecule |
|
|
|
|
MK-3000
Mechanism of Action: MK-3000 is an investigational tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway.
This program is in a Phase 2/3 study.
MK-3000 was acquired as part of the acquisition of Eyebiotech Limited (EyeBio).
|
Ophthalmology |
|
Tri-specific antibody |
|
|
|
|
MK-1084
Mechanism of Action: MK-1084 is an investigational, oral selective KRAS G12C inhibitor.
MK-1084 is being developed in combination with Keytruda.
MK-1084 is being developed through a collaboration with Taiho Pharmaceutical Co. Ltd and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd.
|
Oncology |
Non-small cell lung cancer
|
|
|
Small molecule |
|
|
|
|
raludotatug deruxtecan
(MK-5909)
Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.
Raludotatug deruxtecan is being developed in collaboration with Daiichi Sankyo.
|
Oncology |
Bladder cancer
(REJOICE-PanTumor01; NCT06660654)
|
|
|
Biliary cancer
(REJOICE-GI01; NCT06864169)
|
|
|
Cervical cancer
(REJOICE-PanTumor01; NCT06660654)
|
|
|
Colorectal cancer
(REJOICE-GI01; NCT06864169)
|
|
|
Endometrial cancer
(REJOICE-PanTumor01; NCT06660654)
|
|
|
Gastric cancer
(REJOICE-GI01; NCT06864169)
|
|
|
Ovarian cancer
(REJOICE-Ovarian01; NCT06161025)
|
|
|
Pancreatic cancer
(REJOICE-GI01; NCT06864169)
|
|
|
Renal cell carcinoma
(REJOICE-PanTumor01; NCT06660654)
|
|
|
Small cell lung cancer
(KEYNOTE-B98, NCT04938817)
|
|
|
Antibody-drug conjugate |
|
|
|
|
MK-8527
Mechanism of Action: MK-8527 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) of HIV-1.
|
Antiviral |
|
Small molecule |
|
|
|
|
MK-6194
Mechanism of Action: MK-6194 is an investigational IL-2 mutein.
MK-6194 was acquired as part of the acquisition of Pandion Therapeutics.
|
Immunology |
|
Therapeutic protein |
|
|
|
|
patritumab deruxtecan
(MK-1022)
Mechanism of Action: Patritumab deruxtecan is an investigational antibody-drug conjugate that consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.
Patritumab deruxtecan is being developed in collaboration with Daiichi Sankyo.
*In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. MSD is working with Daiichi Sankyo to address FDA feedback.
|
Oncology |
Previously treated locally advanced or metastatic EGFR-mutated NSCLC
(HERTHENA-Lung01; NCT04619004)
|
Under review (US*) |
|
Non-small cell lung cancer (EU)
(HERTHENA-Lung02; NCT05338970)
|
|
|
Biliary tract cancer
(MK-1022-011; NCT06596694)
|
|
|
Bladder cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Breast
(HERTHENA-Breast-03; NCT06797635, NCT06686394)
|
|
|
Cervical cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Colorectal cancer
|
|
|
Endometrial cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Esophageal cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Gastric cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Hepatocellular carcinoma
|
|
|
Head and neck squamous cell cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Melanoma
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Ovarian cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Pancreatic cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Prostate cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Antibody-drug conjugate |
|
|
|
|
ifinatamab deruxtecan (MK-2400)
Mechanism of Action: Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.
Ifinatamab deruxtecan is being developed in collaboration with Daiichi Sankyo.
|
Oncology |
Small cell lung cancer
(IDeate-Lung02; NCT06203210)
|
|
|
Esophageal cancer
(IDeate-Esophageal01; NCT06644781)
|
|
|
Biliary Tract Cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Bladder cancer
(IDeate-PanTumor02;NCT06330064)
|
|
|
Breast cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Cervical cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Colorectal cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Endometrial cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Hepatocellular carcinoma
(IDeate-PanTumor02; NCT06330064)
|
|
|
Head and neck squamous cell carcinoma
|
|
|
Melanoma
(IDeate-PanTumor02; NCT06330064)
|
|
|
Ovarian cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Pancreatic cancer
(IDeate-PanTumor02; NCT06330064)
|
|
|
Monoclonal antibody |
|
|
|
|
tulisokibart
(MK-7240)
Mechanism of Action: Tulisokibart is an investigational humanized monoclonal antibody directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A).
Tulisokibart was acquired as part of the acquisition of Prometheus Biosciences, Inc.
|
Immunology |
Crohn’s disease
(NCT06430801; NCT06651281)
|
|
|
Ulcerative colitis
|
|
|
Systemic sclerosis
|
|
|
Monoclonal antibody |
|
|
|
|
bomedemstat
(MK-3543)
Mechanism of Action: Bomedemstat is an investigational lysine-specific demethylase-1 (LSD1) inhibitor.
Bomedemstat was acquired as part of the acquisition of Imago BioSciences, Inc.
|
Oncology |
Myeloproliferative disorders
(NCT06079879; NCT06456346; NCT06351631)
|
|
|
Small molecule |
|
|
|
|
subcutaneous pembrolizumab
(MK-3475A)
Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
|
Oncology |
Previously approved solid tumors
(NCT05722015; NCT06698042)
|
Under review (US, EU) |
|
Cutaneous squamous cell carcinoma
|
|
|
Hematological malignancies
(NCT06504394;NCT06099782)
|
|
|
Monoclonal antibody fixed-dose combination |
|
|
|
|
islatravir + lenacapavir
(MK-8591D)
Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor.
MK-8591D is on FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
Islatravir is being developed under an with the Yamasa Corporation. The combination of islatravir and lenacapavir is being developed in a collaboration with Gilead Sciences, Inc.
|
Antiviral |
HIV-1 infection
(ISLEND-1; NCT06630286, ISLEND-2; NCT06630299, NCT05052996)
|
|
|
Small molecule fixed-dose combination |
|
|
|
|
sacituzumab tirumotecan
(MK-2870)
Mechanism of Action: Sacituzumab tirumotecan is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload.
Sacituzumab tirumotecan is being developed as monotherapy and/or in combination with KEYTRUDA.
Sacituzumab tirumotecan is being developed in collaboration with Sichuan Kelun-Biotech.
|
Oncology |
Breast cancer
(NCT06312176; NCT06393374)
|
|
|
Cervical cancer
(TroFuse-020; NCT06459180)
|
|
|
Endometrial cancer
|
|
|
Gastric cancer
(TroFuse-015; NCT06356311)
|
|
|
NSCLC
(NCT06074588, NCT06170788;
NCT06422143; NCT06305754; TroFuse-019; NCT06312137)
|
|
|
Ovarian cancer
(TroFuse-022; NCT06824467)
|
|
|
Biliary tract cancer
|
|
|
Bladder cancer
(TroFuse-027; NCT06637423)
|
|
|
Colorectal cancer
|
|
|
Neoplasm malignant
|
|
|
Pancreatic cancer
|
|
|
Antibody-drug conjugate |
|
|
|
|
islatravir + doravirine
(MK-8591A)
Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Doravirine is a pyridinone non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.
MK-8591A is on FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
Islatravir is being developed under an agreement with the Yamasa Corporation.
|
Antiviral |
HIV-1 infection
(MK-8591A-033; NCT04776252, ILLUMINATE SWITCH A; NCT04223778, ILLUMINATE NAIVE; NCT04233879, ILLUMINATE SWITCH B; NCT04223791, ILLUMINATE HTE; NCT04233216,
MK-8591A-051; NCT05631093,
MK-8591A-052; NCT05630755,
MK-8591A-053; NCT05705349,
MK-8591A-054; NCT05766501)
|
|
|
Small molecule fixed-dose combination |
|
|
|
|
LYNPARZA®
(MK-7339)
Mechanism of Action: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.
LYNPARZA is being developed as a monotherapy and/or in combination with KEYTRUDA.
LYNPARZA is being developed in collaboration with AstraZeneca.
|
Oncology |
Non-small cell lung cancer
(KEYLYNK-012; NCT04380636, KEYLYNK-008; NCT03976362, KEYLYNK-006; NCT03976323)
|
|
|
Small cell lung cancer
(KEYLYNK-013; NCT04624204)
|
|
|
Small molecule |
|
|
|
|
LENVIMA®
(MK-7902)
Mechanism of Action: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
LENVIMA is being developed in combination with KEYTRUDA.
LENVIMA is being developed in collaboration with Eisai.
|
Oncology |
|
Small molecule |
|
|
|
|
opevesostat
(MK-5684)
Mechanism of Action: Opevesostat is an investigational oral inhibitor of cytochrome P450 11A1.
Opevesostat is being developed in collaboration with Orion.
|
Oncology |
Prostate cancer
(OMAHA1; NCT06136624, OMAHA2a; NCT06136650)
|
|
|
Small molecule |
|
|
|
|
V181
Description: V181 is an investigational quadrivalent dengue vaccine.
|
Vaccines |
|
Vaccine |
|
|
|
|
MK-5475
Mechanism of Action: MK-5475 is an investigational stimulator of soluble Guanylate Cyclase (sGC).
|
Cardiovascular |
PH-COPD
(INSIGNIA-PH-COPD; NCT05612035)
|
|
|
Small molecule |
|
|
|
|
CAPVAXIVE™
(V116)
Description: V116 is a 21-valent pneumococcal conjugate vaccine.
|
Vaccines |
Pneumococcal, adult
(STRIDE-3; NCT05425732, STRIDE-4; NCT05464420, STRIDE-5; NCT05526716, STRIDE-6; NCT05420961, STRIDE-7; NCT05393037, STRIDE-8; NCT05696080, STRIDE-9; NCT05633992, STRIDE-10; NCT05569954)
|
Under review (JPN) |
|
Pneumococcal, child
|
|
|
Vaccine |
|
|
|
|
clesrovimab
(MK-1654)
Mechanism of Action: Clesrovimab is an investigational respiratory syncytial virus (RSV) fusion (F) glycoprotein neutralizing monoclonal antibody.
|
Respiratory |
Respiratory syncytial virus
(NCT04767373, NCT04938830)
|
Under review (US, EU) |
|
Monoclonal antibody |
|
|
|
|
LAGEVRIO™
(MK-4482)
Mechanism of Action: Molnupiravir is an investigational antiviral ribonucleoside prodrug of N-hydroxycytidine (NHC). NHC triphosphate is incorporated into viral RNA by viral RNA polymerase and results in an accumulation of errors in the viral genome leading to inhibition of replication.
LAGEVRIO is being developed under an agreement with Ridgeback Biotherapeutics LP.
LAGEVRIO is available in the U.S. under Emergency Use Authorization.
|
Antiviral |
COVID-19
(MOVe-OUT; NCT04575597, MOVe-NOW;NCT06667700)
|
(US)
|
|
Small molecule |
|
|
|
|
nemtabrutinib
(MK-1026)
Mechanism of Action: Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants.
Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc.
|
Oncology |
Hematological malignancies
(BELLWAVE-001; NCT03162536, BELLWAVE-003; NCT04728893, BELLWAVE-008; NCT05624554,
BELLWAVE-010; NCT05947851
BELLWAVE-011; NCT06136559)
|
|
|
Small molecule |
|
|
|
|
WINREVAIR™
(MK-7962)
Mechanism of Action: Sotatercept is an activin signaling inhibitor that binds to activin A and other TGF-β superfamily ligands.
Sotatercept was acquired as part of the acquisition of Acceleron.
|
Cardiovascular |
Pulmonary arterial hypertension
|
Under review (JPN) |
|
Pulmonary arterial hypertension
(SOTERIA; NCT04796337, ZENITH; NCT04896008, HYPERION; NCT04811092)
|
|
|
Pulmonary hypertension due to Left Heart Disease
(CADENCE; NCT04945460; MOONBEAM; NCT05587712; LIGHTRAY; NCT06664801)
|
|
|
Therapeutic protein |
|
|
|
|
intismeran autogene
(V940)
Mechanism of Action: V940 is an investigational mRNA-based individualized neoantigen therapy targeting tumor associated antigens expressed by a patient’s cancer cells.
V940 is being developed in combination with KEYTRUDA.
V940 is being developed in collaboration with Moderna.
|
Oncology |
Melanoma
(INTerpath-001; NCT05933577)
|
|
|
Non-small cell lung cancer
(INTerpath-002; NCT06077760), INTerpath-009; NCT06623422 )
|
|
|
Bladder cancer
(INTerpath-005; NCT06305767)
|
|
|
Renal cell carcinoma
(INTerpath-004; NCT06307431)
|
|
|
Vaccine |
|
|
|
|
quavonlimab
(MK-1308)
Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands.
Quavonlimab is being developed in combination with KEYTRUDA.
Quavonlimab is being developed under an agreement with Akeso, Inc.
|
Oncology |
Non-small cell lung cancer
|
|
|
Monoclonal antibody |
|
|
|
|
enlicitide decanoate
(MK-0616)
Mechanism of Action: enlicitide decanoate is an investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9).
|
Cardiovascular |
Hypercholesterolemia
(CORALreef Lipids; NCT05952856,
CORALreef Outcomes; NCT06008756,
CORALreef HeFH; NCT05952869,
CORALreef AddOn; NCT06450366,
CORALreef Extension; NCT06492291)
|
|
|
Peptide |
|
|
|
|
islatravir + MK-8507
(MK-8591B)
Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. MK-8507 is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.
Islatravir is being developed under an agreement with the Yamasa Corporation.
|
Antiviral |
HIV-1 infection
(IMAGINE-DR; NCT04564547)
|
|
|
Small molecule fixed-dose combination |
|
|
|
|
quavonlimab + pembrolizumab
(MK-1308A)
Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
Quavonlimab is being developed under an agreement with Akeso, Inc.
|
Oncology |
Renal cell carcinoma
(LITESPARK-012; NCT04736706)
|
|
|
Monoclonal antibody fixed-dose combination |
|
|
|
|
efinopegdutide
(MK-6024)
Mechanism of Action: Efinopegdutide is an investigational dual GLP-1/glucagon receptor agonist.
Efinopegdutide is being developed under an agreement with Hanmi Pharmaceutical.
|
Endocrinology |
Metabolic dysfunction-associated steatohepatitis
(NCT04944992; NCT06465186; NCT05877547; NCT06482112)
|
|
|
Peptide |
|
|
|
|
KEYTRUDA®
(MK-3475) **
Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
**Select KEYTRUDA clinical trials are shown.
|
Oncology |
Resectable locally advanced head and neck cancer carcinoma
|
Under review (US, JPN) |
|
1L unresectable advanced or metastatic malignant pleural mesothelioma
|
Under review (JPN) |
|
Hepatocellular carcinoma (EU)
|
|
|
Ovarian cancer
(KN-B96/ENGOT-ov65; NCT05116189)
|
|
|
Small cell lung cancer
|
|
|
Advanced solid tumors
(KN-158; NCT02628067, KN-051; NCT02332668)
|
|
|
Prostate cancer
(KN-991; NCT04191096, KN-641; NCT03834493, KN-921; NCT03834506)
|
|
|
Monoclonal antibody |
|
|
|
|
zilovertamab vedotin
(MK-2140)
Mechanism of Action: Zilovertamab vedotin is an investigational antibody-drug conjugate that consists of a ROR1-targeting antibody linked to monomethyl auristatin E (MMAE)-containing payload.
Zilovertamab vedotin was acquired as part of the acquisition of VelosBio.
|
Oncology |
Hematological malignancies
(waveLINE-003; NCT05139017, waveLINE-004; NCT05144841, waveLINE-006; NCT05458297, waveLINE-007; NCT05406401; waveLINE-010; NCT06717347)
|
|
|
Antibody-drug conjugate |
|
|
|
|
WELIREG™
(MK-6482)
Mechanism of Action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes.
WELIREG is being developed as a monotherapy and/or in combination with KEYTRUDA.
WELIREG was acquired as part of the acquisition of Peloton Therapeutics, Inc.
|
Oncology |
Advanced, unresectable, or metastatic pheochromocytoma and paraganglioma
(LITESPARK-015; NCT04924075)
|
Under review (US) |
|
Previously treated advanced renal cell carcinoma
(LITESPARK-005; NCT04195750)
|
Under review (JPN) |
|
von Hippel-Lindau (VHL) disease
(LITESPARK-004; NCT03401788)
|
Under review (JPN) |
|
Renal cell carcinoma
(LITESPARK-022; NCT05239728, LITESPARK-012; NCT04736706, LITESPARK-011; NCT04586231)
|
|
|
Small molecule |
